{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T07:31:31Z","timestamp":1791617491569,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"DOI":"10.1186\/s12905-024-03355-x","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T02:02:57Z","timestamp":1727920977000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Survey on adverse events associated with drug therapy for breast cancer patients"],"prefix":"10.1186","volume":"24","author":[{"given":"Fumikata","family":"Hara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadahiro","family":"Izutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Nihei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"3355_CR1","unstructured":"Japanese Breast Cancer Society. Breast Cancer Clinical Practice Guideline. 2022. (in Japanese). Available from URL: https:\/\/jbcs.xsrv.jp\/guideline\/2022\/ Accessed 11 December 2023."},{"key":"3355_CR2","doi-asserted-by":"publisher","first-page":"175883591879332","DOI":"10.1177\/1758835918793326","volume":"3","author":"M Thill","year":"2018","unstructured":"Thill M, Schmidt M. Management of adverse events during cyclin-dependent kinase 4\/6 (CDK4\/6) inhibitor-based treatment in breast cancer. Ther Adv Med Oncol. 2018;3:10:1758835918793326. https:\/\/doi.org\/10.1177\/1758835918793326.","journal-title":"Ther Adv Med Oncol"},{"key":"3355_CR3","doi-asserted-by":"publisher","first-page":"100553","DOI":"10.1016\/j.esmoop.2022.100553","volume":"7","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7:100553. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100553.","journal-title":"ESMO Open"},{"key":"3355_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-021-06480-5","volume":"192","author":"O Gumusay","year":"2022","unstructured":"Gumusay O, Callan J, Rugo HS. Immunotherapy toxicity: identification and management. Breast Cancer Res Treat. 2022;192:1\u201317. https:\/\/doi.org\/10.1007\/s10549-021-06480-5.","journal-title":"Breast Cancer Res Treat"},{"key":"3355_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.breast.2013.09.009","volume":"22","author":"R Barroso-Sousa","year":"2013","unstructured":"Barroso-Sousa R, Santana IA, Testa L, de Melo Gagliato D, Mano MS. Biological therapies in breast cancer: common toxicities and management strategies. Breast. 2013;22:1009\u201318. https:\/\/doi.org\/10.1016\/j.breast.2013.09.009.","journal-title":"Breast"},{"key":"3355_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/00019514-199302010-00007","volume":"2","author":"PD Cleary","year":"1993","unstructured":"Cleary PD, Edgman-Levitan S, Walker JD, Gerteis M, Delbanco TL. Using patient reports to improve medical care: a preliminary report from 10 hospitals. Qual Manag Health Care. 1993;2:31\u20138.","journal-title":"Qual Manag Health Care"},{"key":"3355_CR7","unstructured":"Ministry of Health, Labour and Welfare. Basic Plan to Promote Cancer Control Programs. March 2018 (in Japanese). Available from URL: https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/0000196975.pdf Accessed 11 December 2023."},{"key":"3355_CR8","doi-asserted-by":"publisher","first-page":"e0208118","DOI":"10.1371\/journal.pone.0208118","volume":"14","author":"T Watanabe","year":"2019","unstructured":"Watanabe T, Yagata H, Saito M, Okada H, Yajima T, Tamai N, et al. A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients. PLoS ONE. 2019;14:e0208118. https:\/\/doi.org\/10.1371\/journal.pone.0208118.","journal-title":"PLoS ONE"},{"key":"3355_CR9","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00520-019-05029-z","volume":"28","author":"H Sakai","year":"2020","unstructured":"Sakai H, Umeda M, Okuyama H, Nakamura S. Differences in perception of breast cancer treatment between patients, physicians, and nurses and unmet information needs in Japan. Support Care Cancer. 2020;28:2331\u20138. https:\/\/doi.org\/10.1007\/s00520-019-05029-z.","journal-title":"Support Care Cancer"},{"key":"3355_CR10","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1056\/NEJMp0911494","volume":"362","author":"E Basch","year":"2010","unstructured":"Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010;362:865\u20139. https:\/\/doi.org\/10.1056\/NEJMp0911494.","journal-title":"N Engl J Med"},{"key":"3355_CR11","doi-asserted-by":"publisher","first-page":"103756","DOI":"10.1016\/j.breast.2024.103756","volume":"76","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, et al. 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast. 2024;76:103756. https:\/\/doi.org\/10.1016\/j.breast.2024.103756. 6.","journal-title":"Breast"},{"key":"3355_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jaad.2009.06.063","volume":"63","author":"B Tallon","year":"2010","unstructured":"Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol. 2010;63:333\u20136. https:\/\/doi.org\/10.1016\/j.jaad.2009.06.063.","journal-title":"J Am Acad Dermatol"},{"key":"3355_CR13","first-page":"165","volume":"10","author":"C Pozo-Kaderman","year":"1999","unstructured":"Pozo-Kaderman C, Kaderman RA, Toonkel R. The psychosocial aspects of breast cancer. Nurse Pract Forum. 1999;10:165\u201374.","journal-title":"Nurse Pract Forum"},{"key":"3355_CR14","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.3390\/cancers14123002","volume":"14","author":"N Krawczyk","year":"2022","unstructured":"Krawczyk N, Fehm T, Ruckhaeberle E, Brus L, Kopperschmidt V, Rody A, et al. Post-neoadjuvant Treatment in HER2-Positive breast Cancer: escalation and de-escalation strategies. Cancers (Basel). 2022;14:3002. https:\/\/doi.org\/10.3390\/cancers14123002.","journal-title":"Cancers (Basel)"},{"key":"3355_CR15","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/cancers14081856","volume":"14","author":"RK Gupta","year":"2022","unstructured":"Gupta RK, Roy AM, Gupta A, Takabe K, Dhakal A, Opyrchal M, et al. Systemic therapy de-escalation in early-stage triple-negative breast Cancer: Dawn of a new era? Cancers (Basel). 2022;14:1856. https:\/\/doi.org\/10.3390\/cancers14081856.","journal-title":"Cancers (Basel)"},{"key":"3355_CR16","doi-asserted-by":"publisher","first-page":"dju319","DOI":"10.1093\/jnci\/dju319","volume":"106","author":"DL Hershman","year":"2014","unstructured":"Hershman DL, Tsui J, Meyer J, Glied S, Hillyer GC, Wright JD, et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst. 2014;106:dju319. https:\/\/doi.org\/10.1093\/jnci\/dju319.","journal-title":"J Natl Cancer Inst"},{"key":"3355_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-013-2630-y","volume":"140","author":"E Paplomata","year":"2013","unstructured":"Paplomata E, Zelnak A, O\u2019Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res Treat. 2013;140:453\u201362. https:\/\/doi.org\/10.1007\/s10549-013-2630-y.","journal-title":"Breast Cancer Res Treat"},{"key":"3355_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.breast.2022.10.007","volume":"66","author":"M Shastry","year":"2022","unstructured":"Shastry M, Jacob S, Rugo HS, Hamilton E. Antibody-drug conjugates targeting TROP-2: clinical development in metastatic breast cancer. Breast. 2022;66:169\u201377. https:\/\/doi.org\/10.1016\/j.breast.2022.10.007.","journal-title":"Breast"},{"key":"3355_CR19","doi-asserted-by":"publisher","first-page":"188902","DOI":"10.1016\/j.bbcan.2023.188902","volume":"1878","author":"S Qiu","year":"2023","unstructured":"Qiu S, Zhang J, Wang Z, Lan H, Hou J, Zhang N, et al. Targeting Trop-2 in cancer: recent research progress and clinical application. Biochim Biophys Acta Rev Cancer. 2023;1878:188902. https:\/\/doi.org\/10.1016\/j.bbcan.2023.188902.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"3355_CR20","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","volume":"18","author":"HS Rugo","year":"2017","unstructured":"Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, et al. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017;18:654\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(17)30109-2.","journal-title":"Lancet Oncol"},{"key":"3355_CR21","doi-asserted-by":"publisher","first-page":"e223","DOI":"10.1634\/theoncologist.2019-0382","volume":"25","author":"N Niikura","year":"2020","unstructured":"Niikura N, Nakatukasa K, Amemiya T, Watanabe KI, Hata H, Kikawa Y, et al. Oral care evaluation to prevent oral Mucositis in Estrogen receptor-positive metastatic breast Cancer patients treated with Everolimus (oral Care-BC): a Randomized Controlled Phase III Trial. Oncologist. 2020;25:e223\u201330. https:\/\/doi.org\/10.1634\/theoncologist.2019-0382.","journal-title":"Oncologist"},{"key":"3355_CR22","doi-asserted-by":"publisher","first-page":"E104","DOI":"10.1503\/cjs.019120","volume":"65","author":"A DiPasquale","year":"2022","unstructured":"DiPasquale A, Prus-Czarnecka Z, Delmar L, Peiris L. Clinical and patient-reported outcomes in oncoplastic breast conservation surgery from a single surgeon\u2019s practice in a busy community hospital in Canada. Can J Surg. 2022;65:E104\u201313. https:\/\/doi.org\/10.1503\/cjs.019120.","journal-title":"Can J Surg"},{"key":"3355_CR23","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s10549-021-06126-6","volume":"187","author":"M Ritter","year":"2021","unstructured":"Ritter M, Ling BM, Oberhauser I, Montagna G, Zehnpfennig L, L\u00e9vy J, et al. The impact of age on patient-reported outcomes after oncoplastic versus conventional breast cancer surgery. Breast Cancer Res Treat. 2021;187:437\u201346. https:\/\/doi.org\/10.1007\/s10549-021-06126-6.","journal-title":"Breast Cancer Res Treat"},{"key":"3355_CR24","doi-asserted-by":"publisher","first-page":"5624","DOI":"10.3390\/cancers14225624","volume":"14","author":"EJ Mason","year":"2022","unstructured":"Mason EJ, Di Leone A, Franco A, D\u2019Archi S, Rianna C, Sanchez AM, et al. Oncoplastic breast surgery versus conservative mastectomy in the management of large ductal carcinoma in situ (DCIS): Surgical, Oncological, and patient-reported outcomes. Cancers (Basel). 2022;14:5624. https:\/\/doi.org\/10.3390\/cancers14225624.","journal-title":"Cancers (Basel)"},{"key":"3355_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","volume":"18","author":"SS Faubion","year":"2015","unstructured":"Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of\u3000premature or early menopause and considerations for management. Climacteric. 2015;18:483\u201391. https:\/\/doi.org\/10.3109\/13697137.2015.1020484.","journal-title":"Climacteric"},{"key":"3355_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.maturitas.2009.08.003","volume":"65","author":"LT Shuster","year":"2010","unstructured":"Shuster LT, Rhodes DJ, Gostout BS, Grossardt BR, Rocca WA. Premature menopause or early menopause: long-term health consequences. Maturitas. 2010;65:161\u20136. https:\/\/doi.org\/10.1016\/j.maturitas.2009.08.003.","journal-title":"Maturitas"},{"key":"3355_CR27","doi-asserted-by":"publisher","unstructured":"Palaia I, Caruso G, Di Donato V, Turetta C, Savarese A, Perniola G, et al. Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey. J Gynecol Oncol. 2024;35(e70). https:\/\/doi.org\/10.3802\/jgo.2024.35.e70.","DOI":"10.3802\/jgo.2024.35.e70"},{"key":"3355_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12905-024-03100-4","volume":"24","author":"F Ferrari","year":"2024","unstructured":"Ferrari F, Giannini A. Approaches to prevention of gynecological malignancies. BMC Womens Health. 2024;24:254. https:\/\/doi.org\/10.1186\/s12905-024-03100-4.","journal-title":"BMC Womens Health"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-03355-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-024-03355-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-03355-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T02:03:23Z","timestamp":1727921003000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-024-03355-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3355"],"URL":"https:\/\/doi.org\/10.1186\/s12905-024-03355-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4556792\/v1","asserted-by":"object"}]},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey was approved by the Ethical Review Board (Medical Corporation TOUKEIKAI Kitamachi Clinic ERB) and conducted in accordance with the ethical principles of the Declaration of Helsinki (revised 2013) and in compliance with the Ethical Guidelines for Life Sciences and Medical Research Involving Human Subjects (revised 2022), and the Act on the Protection of Personal Information in Japan. Informed consent was obtained from all individual participants included in the survey via the web-based survey system.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Fumikata Hara, Reiko Nagasaki, Naomi Sakurai, and Shinji Ohno received honorarium from Daiichi Sankyo Co., Ltd. Reiko Minami, Tadahiro Izutani, Takahiro Yoshida, and Ayako Arai are employees of Daiichi Sankyo Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"545"}}